| The Board of Directors includes: | The Board of Scientific Advisors includes: | |
|
Mr. Thomas Auth Dr. Robert E. Carlson Dr. Robert M. Carlson Mr. Richard A. Hoel (Chairman) Mr. Randy K. Geissler Mr. Douglas M. Kratz Mr. Chetan N. Patel |
Dr. Robert E. Carlson Dr. Robert M. Carlson (chairman) Dr. Andrew Hamilton Dr. Thomas J. Kodadek Dr. John M. McCall Dr. Lawrence Que Jr Dr. Mark T. Skoog |
Mr. Thomas Auth
Owner and Chief Executive of Vomela Specialty Company in St. Paul, MN 1990- Present Vomela has seen revenues increase from $3 million in 1990 to over $40 million in 2004. Mr. Auth has been involved as either an investor or a corporate CEO in the acquisition of more than 20 companies. Most notably, Mr.Auth was Chairman and CEO of ITI Technologies, Inc., a global security, life safety, systems software and communications company. Under his leadership ITI experienced tremendous growth and success. The company was recognized three times by Business Week and Forbes magazines as being among the best small companies in America. Mr. Auth was recognized in 1985 as the St. Paul, Minnesota Small Businessman of the Year. In the 20 years that Mr.Auth was CEO of ITI he raised over $120 million in financing and built annual sales to $125 million. In 2000, ITI merged with INTERLOGIX, Inc. which was then sold to General Electric in 2002.
www.vomela.com
Dr. Robert E. Carlson
Founding President of ECOCHEM Research, Inc. Founded 1985; Chaska MN. Research and Development at the Chemistry / Biology Interface. Founding Senior Partner of CAPE Technology LLC. Founded 1996; South Portland, ME. High Performance Immunotechnology Products for Environmental Analysis (www.cape-tech.com). Founding Chairman and President of RECEPTORS LLC Dr. Carlson is the inventor of the Combinatorial Artificial Receptor Array (CARA®) technology and serves as RECEPTORS' President and Principal Investigator. Dr. Carlson has direct experience in the development and commercialization of immunotechnology and pharmaceutical products with over 30 publications and 3 patents in areas relevant to RECEPTORS' goals. Dr. Carlson has applied for over 20 patents on behalf of RECEPTORS LLC.
www.receptorsllc.com
Dr. Robert M. Carlson
Professor, Department of Chemistry, University of Minnesota, Duluth. 1966 - current; Duluth, MN. Cofounder, Apprise Technologies, Duluth, Mn; Optical sensor products for environmental analysis. # Robert M. Carlson has authored over 70 publications and has been listed as an inventor on about 15 patents and patents pending. His research has focused on the development of new methods for the synthesis of biologically-active natural products, environmental analytical chemistry and the development of value-added products derived from the waste streams of forest product industries. Dr. Carlson serves as the chairman of the RECEPTORS' Science Advisory Board. Dr. Carlson has experience in both research and development management and the development of technology based products and companies.
www.d.umn.edu/chem
Randy K. Geissler
Randolph Geissler currently is Chief Executive Officer of Geissler Corporation. He specializes in managing companies and technologies involved in the veterinary science field by selectively discovering or creating technologies and strategically introducing those assets to the markets. Technologies include, among others: radio frequency identification and optical imaging. His vision and implementation are directly responsible for propelling the implantable microchip from "just an idea" to its highly successful current status of more than 100,000,000 microchips implanted in animals worldwide for identification and tracking. He previously served as Chief Executive Officer of Geissler Technologies (2004 - 2008) when he sold the company's expansive product development pipeline. Prior to Geissler Technologies, he served as Chief Executive Officer of Digital Angel Corporation (Amex: DOC) (2000 - 2003) and Destron Fearing (Nasdaq: DFCO) (1993 - 1999), a company he founded thru a merger with his private company Fearing Manufacturing. He took his company public (two times) and has broad experience in product development, electronic miniaturization, application of advanced technologies in new markets, and creating marketing alliances; plus extensive experience in establishing strategic Intellectual Property and Patent portfolio and holds several technology patents.
Dr. Andrew D. Hamilton
Deputy Provost for Science & Technology, Irenee DuPont Professor of Chemistry, Professor Molecular Biophysics & Biochemisty, Yale University. Dr. Hamilton has over 250 publications and 20 patents and patents pending. His research is focused on molecular recognition and the application of artificial receptors to pharmaceutical development. Dr. Hamilton is a world leader in the development and application of artificial receptors
ursula.chem.yale.edu/~hamgrp/
Mr. Richard A. Hoel
Founding shareholder of Winthrop & Weinstine, P.A., a Minneapolis law firm. Founded in 1979
Director and investor in Duke Financial Group, Inc.; Automated Management Technologies, Inc.; Automotive Cooling Products, Inc.; Pyramid Manufacturing, Inc.; Aero Systems Engineering, Inc.; and Minnesota ASE, LLC. General corporate law with an emphasis on mergers and acquisitions. Active investor in start-up and mature companies.
www.winthrop.com
Dr. Thomas J. Kodadek
Professor, Departments of Medicine and Molecular Biology, University of Texas Southwestern Medical Center. Co-Director of the Center for Biomedical Inventions at UT-Southwestern Fellow of the AAAS Dr. Kodadek is the author or co-author of over 100 research articles and two patents in many areas of chemistry and biology. Dr. Kodadek's current research interests include the regulation of gene transcription and the development of new technologies for proteomics research.
kodadeklab.swmed.edu
Mr. Douglas M. Kratz
Chairman, National Bancshares, Inc., Bettendorf, Iowa, a community banking organization with offices in both Iowa and Illinois. Chairman, One Corporation, Naples, Florida, an investment firm with debt/equity holdings in various privately owned entities. Director and a principal investor in JMF Company, a wholesale distribution company based in Bettendorf, Iowa. Active investor in public debt/equity markets.
www.jmfcompany.com
Dr. John M. McCall
John McCall's expertise is drug discovery, risk minimization, and medicinal chemistry. He has worked in a number of diseases including different acute and chronic disorders. He is currently president of PharMac LLC. He began his career as a medicinal chemist with Upjohn and has subsequently held positions with Pharmacia & Upjohn, Pharmacia and Pfizer. John was director of CNS Research with Upjohn, Vice President and Global Head of Chemistry for both Pharmacia and Pharmacia & Upjohn, and Vice Presisent Research with Phizer. John currently chairs a NINDS development team in the spinal muscular atrophy area, serves on thirteen administrative and science advisory boards, consults, participates as a NIH study section member, works with three venture capitol funds, is partner with the Apjohn Group, and has co-founded VBPharma (a company that is targeting new therapies for muscular dystrophy). His Board and Scientific Advisory Board positions include Psychogenics, UCB, CeeTox, Deciphera, Lycera, Synergenics, Michigan High Throughput Screening Center, Verseon, CINRG, Reaction Biology, Scripps, AdmetRx, and PharmOptima. John holds 53 US patents and has over 60 related publications.
www.pharmacllc.com
Mr. Chetan N. Patel
Current owner, Corporate President and co-founder (in 1986) of Scientific Moldings Corporation, Ltd. (SMC) 24 years of experience in plastic research and engineering in the US and abroad. Positions held by Mr. Patel include: Service Engineer, Design Engineer, Project Engineer and Manager of Engineering. These positions were with four highly respected companies in the plastics manufacturing industry. Graduated from the University Of Bombay, India, majoring in Plastics Engineering. Earned a M.S. in Plastics Engineering from the University of Lowell, Lowell, MA.
Dr. Lawrence Que, Jr.
Professor, Department of Chemistry, University of Minnesota, Minneapolis, MN. 1987-present. Director, Center for Metals in Biocatalysis, University of Minnesota, Minneapolis, MN. 1994-present. Dr. Que has over 280 publications and 4 patents. His research is focused on the role of metals in Biocatalysis and the application of metallo complexes to chemical transformation. Dr. Que is a recognized leader in the development of artificial enzymes.
bioinorg.chem.umn.edu/quespace/
Dr. Mark T. Skoog
Partner, Merchant & Gould. 2003-Present; Minneapolis Minnesota. Associate Attorney, Merchant & Gould. 1996-2002; Minneapolis Minnesota. A Ph.D. in Biochemistry, Dr. Skoog practices Intellectual Property law with an emphasis on patent prosecution and client counseling. Before becoming a patent attorney, Dr. Skoog spent a decade as a researcher and research manager in the pharmaceutical industry searching for therapies for inflammatory, autoimmune, and viral diseases. Dr. Skoog's practice areas include obtaining patent protection and evaluating patents in fields including biotechnology, chemistry, and pharmaceuticals.
www.merchant-gould.com